Cancer Biomarkers: Are We Ready for the Prime Time?

A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. In cancer, a biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker might be either a molecule secreted by a tumor or it can be a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis and epidemiology. These markers can be assayed in non-invasively collected biofluids. However, few cancer biomarkers are highly sensitive and specific for cancer detection at the present time. Consequently, biomarkers are not yet ready for routine use due to challenges in their clinical validation for early disease detection, diagnosis and monitoring to improve long-term survival of patients.

[1]  P. Hitchen,et al.  Targeted glycoproteomic identification of cancer cell glycosylation , 2009, Glycobiology.

[2]  A. Partin,et al.  Antibody array profiling reveals serum TSP‐1 as a marker to distinguish benign from malignant prostatic disease , 2007, The Prostate.

[3]  A. Simpson,et al.  Detection of oral and oropharyngeal cancer by microsatellite analysis in mouth washes and lesion brushings. , 2000, Oral oncology.

[4]  Margaret E McLaughlin-Drubin,et al.  Viruses associated with human cancer. , 2008, Biochimica et biophysica acta.

[5]  W. Funkhouser,et al.  Clinical evaluation of a new molecular method for detection of micrometastases in head and neck squamous cell carcinoma. , 2004, Archives of otolaryngology--head & neck surgery.

[6]  E. Van Cutsem,et al.  Tissue Biomarker Development in a Multicentre Trial Context: a Feasibility Study on the PETACC3 Stage II and III Colon Cancer Adjuvant Treatment Trial , 2009, Clinical Cancer Research.

[7]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[8]  J. Gray,et al.  Translational Research Working Group Developmental Pathway for Biospecimen-Based Assessment Modalities , 2008, Clinical Cancer Research.

[9]  A. Melman,et al.  Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. , 1995, Nature medicine.

[10]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[11]  T. Orntoft,et al.  Clinical aspects of altered glycosylation of glycoproteins in cancer , 1999, Electrophoresis.

[12]  Kit S Lam,et al.  Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. , 2006, Journal of proteome research.

[13]  S. Chew,et al.  Identification of molecular markers for the early detection of human squamous cell carcinoma of the uterine cervix , 2002, British Journal of Cancer.

[14]  Jeffrey T. Chang,et al.  Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential , 2009, Proceedings of the National Academy of Sciences.

[15]  D. Saluja,et al.  Differential expression and activation of NF‐κB family proteins during oral carcinogenesis: Role of high risk human papillomavirus infection , 2006 .

[16]  Pauline M. Rudd,et al.  Glycosylation Changes on Serum Glycoproteins in Ovarian Cancer May Contribute to Disease Pathogenesis , 2009, Disease markers.

[17]  Nan Hu,et al.  2D Differential In-gel Electrophoresis for the Identification of Esophageal Scans Cell Cancer-specific Protein Markers* , 2002, Molecular & Cellular Proteomics.

[18]  M. Stoneham.  Electrons in carbon country , 2004, Nature materials.

[19]  T. Isono,et al.  Urinary calreticulin in the diagnosis of bladder urothelial carcinoma , 2009, International journal of urology : official journal of the Japanese Urological Association.

[20]  M. Boxus,et al.  Mechanisms of HTLV-1 persistence and transformation , 2009, British Journal of Cancer.

[21]  Benjamin Geiger,et al.  The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells , 1982, Cell.

[22]  C. Van Waes,et al.  cDNA microarray and bioinformatic analysis of nuclear factor-kappaB related genes in squamous cell carcinoma. , 2007, Methods in molecular biology.

[23]  B. Zetter,et al.  Cancer biomarkers: knowing the present and predicting the future. , 2005, Future oncology.

[24]  Mukesh Verma,et al.  Proteomics for Cancer Biomarker Discovery , 2002 .

[25]  M. Loda,et al.  Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. O’Donovan,et al.  p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep™ smears , 2003, Journal of clinical pathology.

[27]  J. Hirst,et al.  Analysis of the Subunit Composition of Complex I from Bovine Heart Mitochondria*S , 2003, Molecular & Cellular Proteomics.

[28]  H. Hausen.  Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature Reviews Cancer.

[29]  T. Barrette,et al.  Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. , 2002, Cancer research.

[30]  C. Bertozzi,et al.  Glycans in cancer and inflammation — potential for therapeutics and diagnostics , 2005, Nature Reviews Drug Discovery.

[31]  Shigeki Shimizu,et al.  [Molecular abnormalities in lung cancer]. , 2002, Nihon rinsho. Japanese journal of clinical medicine.

[32]  D. McCarthy,et al.  Serum Protein Expression Profiling for Cancer Detection: Validation of a SELDI-Based Approach for Prostate Cancer , 2004, Disease markers.

[33]  S. Gygi,et al.  Quantitative Cancer Proteomics: Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) as a Tool for Prostate Cancer Research*S , 2004, Molecular & Cellular Proteomics.

[34]  Caroline Seydel,et al.  Quantum Dots Get Wet , 2003, Science.

[35]  E. Masini,et al.  Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck , 2002, Cancer.

[36]  J. Ajani,et al.  Molecular epidemiology of genetic susceptibility to gastric cancer: focus on single nucleotide polymorphisms in gastric carcinogenesis. , 2009, American journal of translational research.

[37]  S. Nelson,et al.  DNA-microarray analysis of brain cancer: molecular classification for therapy , 2004, Nature Reviews Neuroscience.

[38]  M. Verma,et al.  Epigenetics in cancer: implications for early detection and prevention. , 2002, The Lancet. Oncology.

[39]  S. D. Lee,et al.  Utility of lentil lectin affinity of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. , 1996, Journal of hepatology.

[40]  Ji Huang,et al.  [Serial analysis of gene expression]. , 2002, Yi chuan = Hereditas.

[41]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[42]  J. Gray,et al.  Genome changes and gene expression in human solid tumors. , 2000, Carcinogenesis.

[43]  J. Weinstein,et al.  Biomarkers in Cancer Staging, Prognosis and Treatment Selection , 2005, Nature Reviews Cancer.

[44]  B. Furie,et al.  Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. , 1984, The New England journal of medicine.

[45]  P. Carroll,et al.  CpG Hypermethylation of MDR1 Gene Contributes to the Pathogenesis and Progression of Human Prostate Cancer , 2004, Cancer Research.

[46]  G. Lippi,et al.  Prostate-specific antigen, prostate cancer, and disorders of hemostasis. , 2009, Seminars in thrombosis and hemostasis.

[47]  A W Partin,et al.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.

[48]  F. Montorsi,et al.  Survivin as a Prognostic Marker for Urothelial Carcinoma of the Bladder: A Multicenter External Validation Study , 2009, Clinical Cancer Research.

[49]  Daisy R. Lee,et al.  Molecular quality of exfoliated cervical cells: implications for molecular epidemiology and biomarker discovery. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[50]  Meeting report: mitochondrial DNA and cancer epidemiology. , 2007, Cancer research.

[51]  Rajiv Dhir,et al.  Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. , 2005, Cancer research.

[52]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[53]  B. Weigl,et al.  Lab-on-a-chip for drug development. , 2003, Advanced drug delivery reviews.

[54]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[55]  Y. Mechref,et al.  Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets. , 2009, Journal of proteome research.

[56]  H. Banerjee,et al.  Use of nanotechnology for the development of novel cancer biomarkers , 2006, Expert review of molecular diagnostics.

[57]  Samir Gupta,et al.  Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. , 2003, Annals of internal medicine.

[58]  J. McDougall,et al.  Telomerase activity and expression of telomerase RNA component and telomerase catalytic subunit gene in cervical cancer. , 1998, The American journal of pathology.

[59]  Mukesh Verma,et al.  Proteomic maps of the cancer-associated infectious agents. , 2005, Journal of proteome research.

[60]  H. Keer,et al.  Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. , 1989, The Journal of urology.

[61]  M. Verma,et al.  Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations. , 2006, Critical reviews in oncology/hematology.

[62]  D. Katsaros,et al.  Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. , 2003, Cancer research.

[63]  M. Kattan,et al.  Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  M. Verma.  Biomarkers for Risk Assessment in Molecular Epidemiology of Cancer , 2004, Technology in cancer research & treatment.

[65]  Michael W Kattan,et al.  The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  F. Gilliland,et al.  Gene Promoter Methylation in Plasma and Sputum Increases with Lung Cancer Risk , 2005, Clinical Cancer Research.

[67]  D. Dinulescu,et al.  Focused glycomic analysis of the N‐linked glycan biosynthetic pathway in ovarian cancer , 2008, Proteomics.

[68]  王晓燕.  Arch Intern Med:住院增加老年人出院后骨折危险 , 2009 .

[69]  R. Aggarwal,et al.  Plasma and urine biomarkers in acute viral hepatitis E , 2009, Proteome Science.

[70]  S. Shenouda,et al.  MicroRNA function in cancer: oncogene or a tumor suppressor? , 2009, Cancer and Metastasis Reviews.

[71]  Mukesh Verma,et al.  The promise of biomarkers in cancer screening and detection. , 2002, Trends in molecular medicine.

[72]  Phil Gold,et al.  DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES , 1965, The Journal of experimental medicine.

[73]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[74]  Baruch S Blumberg,et al.  Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[75]  D. Seminara,et al.  Genetic and Epigenetic Biomarkers in Cancer , 2012, Molecular Diagnosis & Therapy.

[76]  Samir Gupta,et al.  Test Characteristics of -Fetoprotein for Detecting Hepatocellular Carcinoma in Patients with Hepatitis C , 2003, Annals of Internal Medicine.

[77]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[78]  S. Rodenhuis,et al.  K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.

[79]  D. Saluja,et al.  Differential expression and activation of NF-kappaB family proteins during oral carcinogenesis: Role of high risk human papillomavirus infection. , 2006, International journal of cancer.

[80]  V. Bettinardi,et al.  [11C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[81]  Brian J Zikmund-Fisher,et al.  Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study). , 2009, Archives of internal medicine.

[82]  M. Verma.  Pancreatic Cancer Epidemiology , 2005, Technology in cancer research & treatment.

[83]  G. Tsongalis,et al.  MicroRNAs: novel biomarkers for human cancer. , 2009, Clinical chemistry.

[84]  E. Petricoin,et al.  Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.

[85]  R. Brakenhoff,et al.  Molecular assays for the diagnosis of minimal residual head-and-neck cancer: methods, reliability, pitfalls, and solutions. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[86]  Mukesh Verma,et al.  Proteomic analysis of cancer-cell mitochondria , 2003, Nature Reviews Cancer.

[87]  Chan Zeng,et al.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  Jicai Zhang,et al.  Hypermethylation of Tumor Suppressor Genes BRCA1, p16 and 14-3-3s in Serum of Sporadic Breast Cancer Patients , 2007, Oncology Research and Treatment.

[89]  Shou-Dong Lee,et al.  Utility of lentil lectin affinity of α-fetoprotein in the diagnosis of hepatocellular carcinoma , 1996 .

[90]  G. Zheng,et al.  Optical Molecular Imaging: From Single Cell to Patient , 2008, Clinical pharmacology and therapeutics.

[91]  J. Chin,et al.  NMP22 is predictive of recurrence in high-risk superficial bladder cancer patients. , 2009, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[92]  C. Sawyers.  The cancer biomarker problem , 2008, Nature.

[93]  B. Vikram.  The PSA conundrum. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[94]  D. Ferrigno,et al.  Lung tumour markers in oncology practice: a study of TPA and CA125 , 2002, British Journal of Cancer.

[95]  M. Yanada.  [Treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.

[96]  Ram D. Sriram,et al.  Data standards for proteomics: mitochondrial two-dimensional polyacrylamide gel electrophoresis data as a model system. , 2004, Mitochondrion.

[97]  C. O'Morain,et al.  Helicobacter pylori Infection , 1994 .

[98]  H. Nisenbaum,et al.  HER-2/neu Overexpression as a Predictor for the Transition from In situ to Invasive Breast Cancer , 2009, Cancer Epidemiology Biomarkers & Prevention.

[99]  M. Verma,et al.  Available online at www.sciencedirect.com R , 2002 .

[100]  Shou-Dong Lee,et al.  Des-γ-Carboxy (Abnormal) Prothrombin as a Serum Marker of Primary Hepatocellular Carcinoma , 1984 .

[101]  J. Christensen,et al.  c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. , 2005, Cancer letters.

[102]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[103]  M. Barry,et al.  PSA screening for prostate cancer: the current controversy--a viewpoint. Patient Outcomes Research Team for Prostatic Diseases. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[104]  M. Verma,et al.  Application of mitochondrial genome information in cancer epidemiology. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[105]  J. Lafitte,et al.  Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. , 2001, The European respiratory journal.

[106]  R. Dahiya,et al.  Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer. , 2004, Biochemical and biophysical research communications.

[107]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.

[108]  David Sidransky,et al.  Emerging molecular markers of cancer , 2002, Nature Reviews Cancer.

[109]  M. Ohue,et al.  Comprehensive clinico-glycomic study of 16 colorectal cancer specimens: elucidation of aberrant glycosylation and its mechanistic causes in colorectal cancer cells. , 2009, Journal of proteome research.

[110]  H. Kimura,et al.  Enhanced expression of Mcm proteins in cancer cells derived from uterine cervix. , 2003, European journal of biochemistry.

[111]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  D. Welch,et al.  Metastamir: the field of metastasis-regulatory microRNA is spreading. , 2009, Cancer research.

[113]  B. Seshi.  An integrated approach to mapping the proteome of the human bone marrow stromal cell , 2006, Proteomics.

[114]  H. Friess,et al.  Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders , 2001, Gut.

[115]  B. King,et al.  p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer , 2005, Journal of Clinical Pathology.